Factors associated with local-regional recurrence after a negative sentinel node dissection: Results of the ACOSOG Z0010 trial

Annals of Surgery

Volumn 256, Issue 3, 2012, Pages 428-436

  Hunt, Kelly K ^a   Ballman, Karla V ^b   McCall, Linda M ^d   Boughey, Judy C ^c   Mittendorf, Elizabeth A ^a   Cox, Charles E ^e   Whitworth, Pat W ^f   Beitsch, Peter D ^g   Leitch, A Marilyn ^h   Buchholz, Thomas A ^a   Morrow, Monica A ⁱ   Giuliano, Armando E ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Division of Biomedical Statistics and Informatics   (United States)

^c MAYO CLINIC   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f Nashville Breast Center   (United States)

^g Dallas Surgical Group   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

breast cancer; local regional recurrence; sentinel lymph node biopsy

Indexed keywords

EOSIN; ESTROGEN RECEPTOR; HEMATOXYLIN; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CONFERENCE PAPER; DISTANT METASTASIS; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL METASTASIS; LOCAL REGIONAL RECURRENCE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; REGIONAL METASTASIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SYSTEMIC THERAPY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGRESSION ANALYSIS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84865468114     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182654494     Document Type: Conference Paper

References (28)

1. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394-399; discussion 399-401.
2. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98:599-609. (Pubitemid 43904843)
3. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymphnode resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881-888. (Pubitemid 47488052)
4. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010;251:595-600.
5. Bergkvist L, de Boniface J, J̈onsson PE, et al. Axillary recurrence rate after negative sentinel node biopsy in breast cancer. Three-year follow-up of the Swedish multicenter cohort study. Ann Surg. 2008;247:150-156.
6. Kim HJ, Son BH, Park EW, et al. Axillary recurrence after negative sentinel lymph node biopsy. Breast Cancer Res Treat 2009;114:301-305.
7. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically nodenegative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-933.
8. Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM Trial. Ann Surg. 2008;247:207-213. (Pubitemid 351156760)
9. Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385-393.
10. Posther KE, McCall LM, Blumencranz PW, et al. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Ann Surg. 2005;242:593-599; discussion 599-602.
11. Fisher LD, LinDY. Time-dependent covariates in theCox proportional-hazards regression model. Annu Rev Public Health. 1999;20:145-157. (Pubitemid 29242575)
12. Gooley TA, LeisenringW, Crowley J, et al. Estimation of failure probabilities in the presence of competing risk: new representations of old estimators. Stat Med. 1999;18:695-706. (Pubitemid 29126745)
13. Imoto S,WadaN,MurakamiK, et al. Prognosis of breast cancer patients treated with sentinel node biopsy in Japan. Jpn J Clin Oncol. 2004;34:452-456. (Pubitemid 43115290)
14. Fisher B, Wolmark N, Redmond C, et al. Findings from NSABP Protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer. 1981;48:1863-1872. (Pubitemid 11022890)
15. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-432; discussion 432-3.
16. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-575.
17. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
18. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;14:2373-2378.
19. Voduc KD, Cheang MCU, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684-1691.
20. Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419-1426.
21. Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomywithout adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29:2852-2858.
22. Ho AY, Gupta G, King TA, et al. Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy [published online ahead of print March 5, 2012]. Cancer. doi: 10.1002/cncr.27480.
23. Rakha EA, Martin S, Lee AH, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118:3670-3680.
24. Rakha EA, El-SayedME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26:3153-3158.
25. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12:207.
26. Wasif N, Ko CY, Farrell J, et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010;17:2312-2320.
27. Yi M, Mittendorf EA, Cormier JN, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011;29:4654-4661.
28. Early Breast Cancer Trialists Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet. 2011;378:1707-1716.